Welcome to our dedicated page for Universe Pharmaceuticals SEC filings (Ticker: UPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings and related disclosures for Universe Pharmaceuticals Inc. (UPC), a pharmaceutical producer and distributor in China focused on traditional Chinese medicine derivatives and third-party healthcare products. The company files reports as a foreign private issuer, and these documents offer detailed insight into its operations, financial condition, and corporate actions.
Key filings for Universe Pharmaceuticals include annual reports on Form 20-F, which present audited financial statements, risk factors, business descriptions, and information on traditional Chinese medicine derivatives (TCMD) products and third-party products. Interim financial information and significant corporate events are furnished on Form 6-K, such as financial highlights for the six months ended March 31, 2025, including revenue breakdowns between TCMD and third-party products, gross margin data, operating expenses, and net income or loss.
Universe Pharmaceuticals also uses Form 6-K to report corporate governance and capital structure matters. Examples include notices and proxy statements for annual general meetings of shareholders, results of shareholder votes, and details of capital reorganizations. One 6-K describes a capital reorganization involving a reduction in par value of issued ordinary shares, subdivision and alteration of authorized share capital, and the creation of new share classes with specified voting rights and conversion features, along with the redesignation of existing issued shares into those new classes.
Filings further document equity financing activities, such as registered direct offerings made under an effective shelf registration statement on Form F-3, as well as information about share consolidations (reverse share splits) and changes in authorized share capital. Listing-related developments, including Nasdaq notifications about minimum bid price, market value of publicly held shares, and delayed Form 20-F filings, may appear in 6-K reports as well.
On this page, AI-powered tools can help summarize lengthy filings, highlight key figures and trends, and point out important sections on topics such as revenue composition, operating performance, capital structure, and shareholder approvals. Users can review Forms 20-F and 6-K, along with other available documents, to understand Universe Pharmaceuticals’ regulatory disclosures and historical reporting.
Universe Pharmaceuticals INC has confirmed that all conditions for its dual-class share structure have been met and that the structure will become effective on the Nasdaq Capital Market on February 13, 2026. From that date, its Class A ordinary shares will continue trading under the symbol “UPC” with the same CUSIP.
The company amended and restated its memorandum and articles of association, changing its authorized share capital to US$20,000 divided into 1,800,000,000 Class A ordinary shares and 200,000,000 Class B ordinary shares, each with a par value of US$0.00001. This formalizes a new capital and voting structure while leaving the trading symbol and market listing unchanged.
Universe Pharmaceuticals INC, a Cayman Islands holding company with operations in China, files its annual report for the year ended September 30, 2025. The company reports revenues declining from
Universe Pharmaceuticals INC reported that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together beneficially own 28,111 ordinary shares, representing 4.9% of the company’s ordinary shares as of the event date. All three reporting persons have no sole voting or dispositive power over these shares, but share voting and dispositive power for the full 28,111 shares. They certify that the securities were acquired and are held on a passive basis, not for the purpose of changing or influencing control of Universe Pharmaceuticals.
Universe Pharmaceuticals Inc. reported the results of shareholder votes on corporate proposals. Five directors — Gang Lai, Lin Yang, Jiawen Pang, Ding Zheng and Yongping Yu — were re-elected, each receiving strong majority support, with two directors above
Universe Pharmaceuticals INC reported that its 2025 annual general meeting of shareholders, originally convened on August 26, 2025, could not proceed because there were not enough shares represented to meet the required quorum. As a result, the meeting was formally adjourned to September 2, 2025 at 10:00 a.m. Beijing time.
The rescheduled meeting will take place at the company’s principal office at 265 Jingjiu Avenue in the Jinggangshan Economic and Technological Development Zone in Ji’an City, Jiangxi, China. The notice confirms that the company’s chief executive officer, Gang Lai, authorized this report.